Allurion Technologies Inc.

OTCPK:ALUR Stock Report

Market Cap: US$10.5m

Allurion Technologies Management

Management criteria checks 4/4

Allurion Technologies' CEO is Shantanu Gaur, appointed in Jan 2009, has a tenure of 17.33 years. total yearly compensation is $319.20K, comprised of 97.1% salary and 2.9% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $43.42K. The average tenure of the management team and the board of directors is 2.3 years and 3.5 years respectively.

Key information

Shantanu Gaur

Chief executive officer

US$319.2k

Total compensation

CEO salary percentage97.12%
CEO tenure17.3yrs
CEO ownership0.4%
Management average tenure2.3yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

ALUR: Expanded Brazil Hospital Network Will Drive Obesity Therapy Access

Narrative Update on Allurion Technologies: Analyst Price Target Revision Analysts have raised their price target for Allurion Technologies from $5.83 to $7.00. They cite improved revenue growth projections and a slight uplift in expected profit margin as the primary factors behind the upward revision.

Expanding Obesity Solutions Will Boost Prospects Amid Launch Uncertainties

A significant reduction in consensus revenue growth forecasts has driven the analyst price target for Allurion Technologies down from $8.38 to $5.83. What's in the News Allurion Technologies was unable to file its next 10-Q by the required SEC deadline.

Expanding Obesity Solutions Will Boost Prospects Amid Launch Uncertainties

With consensus forecasts for both revenue growth and net profit margin remaining steady, analysts have left their fair value estimate for Allurion Technologies unchanged at $8.38. What's in the News Allurion Technologies announced a strategic Canadian distribution partnership with Minogue Medical Inc., leveraging Minogue's national network of obesity care providers to expand access to Allurion's metabolically healthy weight loss program.
User avatar

Low-dose GLP-1 Combo And FDA Approval Will Expand Obesity Care

The combination therapy approach and clinical advancements are set to drive increased revenue and expand market share in obesity and related treatments.

Take Care Before Jumping Onto Allurion Technologies Inc. (NYSE:ALUR) Even Though It's 42% Cheaper

Nov 15
Take Care Before Jumping Onto Allurion Technologies Inc. (NYSE:ALUR) Even Though It's 42% Cheaper

CEO Compensation Analysis

How has Shantanu Gaur's remuneration changed compared to Allurion Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$319kUS$310k

-US$29m

Sep 30 2025n/an/a

-US$32m

Jun 30 2025n/an/a

-US$12m

Mar 31 2025n/an/a

-US$11m

Dec 31 2024US$3mUS$620k

-US$7m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$661kUS$355k

-US$85m

Sep 30 2023n/an/a

-US$76m

Jun 30 2023n/an/a

-US$69m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$3mUS$295k

-US$41m

Compensation vs Market: Shantanu's total compensation ($USD319.20K) is below average for companies of similar size in the US market ($USD623.53K).

Compensation vs Earnings: Shantanu's compensation has been consistent with company performance over the past year.

CEO

Shantanu Gaur (38 yo)

17.3yrs
Tenure
US$319,200
Compensation

Dr. Shantanu K. Gaur, M.D. co-founded Allurion Technologies, Inc. in 2009 and has been its Chief Executive Officer since January 1, 2018 and also serves as its President and had been its Secretary. Dr. Gau...

Leadership Team

NamePositionTenureCompensationOwnership
Shantanu Gaur
Co-Founder17.3yrsUS$319.20k0.41%
$ 43.4k
Ojas Buch
Chief Operating Officer1.9yrsUS$457.00k0.068%
$ 7.2k
Brendan Gibbons
Chief Legal & People Officer and Secretary2.3yrsUS$457.00k0.069%
$ 7.3k
Samuel Levy
Co-Founder17.3yrsno datano data
Ram Chuttani
MD & Founding Partnerno datano datano data
Alexandra van Stap
Vice President of Global Marketingno datano datano data
Laurent Laffineur
Vice President of International Sales & Marketing1.3yrsno datano data
2.3yrs
Average Tenure
49yo
Average Age

Experienced Management: ALUR's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Shantanu Gaur
Co-Founder16.7yrsUS$319.20k0.41%
$ 43.4k
Robert S. Langer
Chairman of Scientific Advisory Board3.5yrsno datano data
Michael Davin
Independent Director8.6yrsUS$26.88k0.0080%
$ 844.6
S. Ishrak
Chairman & Lead Independent Director2.8yrsUS$26.25k0.19%
$ 19.9k
Larson Hudson
Independent Director2.8yrsUS$24.06k0.0040%
$ 422.3
Harold Solomon
Medical Advisorno datano datano data
Krishna Gupta
Independent Director9.3yrsUS$24.63k0.33%
$ 34.9k
John Morton
Medical Advisorno datano datano data
Robert Richey
Independent Director1.4yrsUS$11.25kno data
Bruce Schirmer
Medical Advisorno datano datano data
Jordan Busch
Medical Advisorno datano datano data
E.M.H. Mathus-Vliegen
Medical Advisorno datano datano data
3.5yrs
Average Tenure
55yo
Average Age

Experienced Board: ALUR's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/03 13:55
End of Day Share Price 2026/05/01 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allurion Technologies Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeChardan Capital Markets, LLC
Michael ToomeyJefferies LLC
Matthew TaylorJefferies LLC